APA

Heidari M., Zarei M., Hosseini S. M. R., Taghvaei R., Maleki H., Tabrizi M., Fallah J. & Akhondzadeh S. (20150608). Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. : International clinical psychopharmacology.

Chicago

Heidari Mahnaz, Zarei Maryam, Hosseini Seyed M R, Taghvaei Rheleh, Maleki Haleh, Tabrizi Mina, Fallah Jalil and Akhondzadeh Shahin. 20150608. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. : International clinical psychopharmacology.

Harvard

Heidari M., Zarei M., Hosseini S. M. R., Taghvaei R., Maleki H., Tabrizi M., Fallah J. and Akhondzadeh S. (20150608). Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. : International clinical psychopharmacology.

MLA

Heidari Mahnaz, Zarei Maryam, Hosseini Seyed M R, Taghvaei Rheleh, Maleki Haleh, Tabrizi Mina, Fallah Jalil and Akhondzadeh Shahin. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. : International clinical psychopharmacology. 20150608.